|
|
|
|
|
|
by rayiner
2643 days ago
|
|
|
That’s an irrelevant distinction. The possibility of an acquisition is what fuels these biotech startups to invest in the first place. It doesn’t make a difference whether J&J is paying researchers or buying the startup that pays the researchers. As to government funding, mentioned below, the 90/10 rule applies in pharma as much as anything. The last 10% is 90% of the work. |
|
|